New chief medical officer at PTC Therapeutics

Tuyen Ong has been promoted to chief medical officer at US pharma company PTC Therapeutics (NASDAQ: PTCT).

Dr Ong joined PTC in 2014 as senior vice president and head of clinical development and translational research, and in his new role he succeeds Robert Spiegel, who will remain active in a consulting role supporting the company’s development programs and its global clinical and regulatory activities.

Stuart Peltz, PTC’s chief executive, said: “Tuyen has been a valuable addition to the PTC team, bringing a wealth of industry experience and drug development expertise. He will continue to play an important role in the development of Translarna (ataluren) for rare genetic disorders as well as the advancement of our company pipeline. I thank Bob for his significant contributions to PTC over the last five years. He has worked closely with Tuyen and the entire clinical team in advance of this transition to lay the groundwork to support our future clinical and regulatory milestones.”